- Version
- Download 74124
- File Size 0.00 KB
- File Count 1
- Create Date June 13, 2026
- Last Updated June 13, 2026
Improvement of Glucose Variability and Weight Management with Administration of Tirzepatide (Mounjaro)
Author(s): Hisako Yamashita1, Hiroshi Bando1,2,3iD*, Yuka Shinohara1, Sayuri Matsuzaki1, Miyo Tanizaki1, Yoshinobu Kato1
1Kanaiso Hospital, Tokushima, Japan
2Japan Low Carbohydrate Diet Promotion Association, Kyoto, Japan
3Tokushima University / Medical Research, Tokushima, Japan
Corresponding Author: Hiroshi Bando ORCiD
Address: Tokushima University /Medical Research, Nakashowa 1-61, Tokushima 770-0943, Japan.
Received date: 02 May 2026; Accepted date: 01 June 2026; Published date: 09 June 2026
Citation: Yamashita H, Bando H, Shinohara Y, Matsuzaki S, Tanizaki M, Kato Y. Improvement of Glucose Variability and Weight Management with Administration of Tirzepatide (Mounjaro). Asp Biomed Clin Case Rep. 2026 Jun 09;9(2):107-11.
Copyright © 2026 Yamashita H, Bando H, Shinohara Y, Matsuzaki S, Tanizaki M, Kato Y. This is an open-access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium provided the original work is properly cited.
Keywords: Tirzepatide, Type 2 Diabetes, Pulse Wave Velocity, Gastroesophageal Reflux Disease, Dual GIP/GLP-1 Receptor Agonists, SURMOUNT Trials
Abbreviations: ABI: Ankle-Brachial Index; baPWV: Brachial-Ankle Pulse Wave Velocity; BMI: Body Mass Index; GERD: Gastroesophageal Reflux Disease; GI-AE: Gastrointestinal Adverse Effect; GIP: Glucose-Dependent Insulinotropic Polypeptide; GLP-1: Glucagon-Like Peptide-1; HbA1c: Hemoglobin A1c; PWV: Pulse Wave Velocity; SURMOUNT: Study of Tirzepatide in Participants with Obesity or Overweight; T2D: Type 2 Diabetes.
Abstract
The patient was a 71-year-old female. She was diagnosed with type 2 diabetes (T2D) in July 2024, followed by hypertension and gastroesophageal reflux disease (GERD). Her physique was 155 cm in height and 86.4 kg in weight, with a BMI of 36.0 kg/m². Pulse wave velocity (PWV) showed brachial-ankle PWV (baPWV) values of 2139/2277 and ankle-brachial index (ABI) values of 1.12/1.09. She was treated with tirzepatide (Mounjaro) from October 2025. Changes in HbA1c and body weight were from 7.1% to 6.6% and from 86.4 kg to 82.6 kg over 5 months, respectively. She reported a decreased appetite compared to before, with no gastrointestinal adverse effects (GI-AEs). Consequently, tirzepatide showed a satisfactory clinical effect in this case.
View PDF